We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.

Barrett's Esophagus

Barrett's Esophagus is the only known precursor of Esophageal Adenocarcinoma.1

Barrett’s Esophagus (BE) is the only known precursor of Esophageal Adenocarcinoma (EAC)1, which is currently the fastest growing cancer where 4 out of 5 patients die within 5 years of their diagnosis.2
The unfortunate statistics are the result of only 1 in 4 cases of EAC being diagnosed within 1 year of normal index endoscopy in patients with BE.2

Cellvizio® Clinical Value

Compared to the standard 4-quadrant biopsy (Seattle) protocol, the detection rate of BE improved to 28% compared to 12%.3
This allows physicians to better target biopsies within focused areas of concern, augmenting conventional technologies and techniques and improving the ability to detect and monitor cellular changes which cannot be observed with HD-WLE or Narrow Band Imaging (NBI).4,5
This helps improve diagnostic yield and increase the detection of dysplastic lesions from 34% to 68%.4


Cellvizio® is part of routine clinical practice

See how Dr. Joseph Burnette, a general surgeon with special interest in reflux uses Cellvizio® on all his chronic reflux patients.

Tissue Characterization using Cellvizio® GastroFlex UHD Miniprobe

Squamous Epithelium

Cellvizio® provides real-time in vivo imaging 

Intestinal Metaplasia

Cellvizio® provides real-time in vivo imaging 


Cellvizio® provides real-time in vivo imaging 

Patient Management

Cellvizio® leads to better informed patient management by providing additional advanced imaging, enabling real-time tissue assessment and early detection.

Physicians are able to rule-in or rule-out intestinal metaplasia when there are Gastroesophageal Reflux Disease (GERD) symptoms, and can monitor disease progression for BE or Low Grade Dysplasia/High Grade Dysplasia.4,5,6

Physicians also are able to define the location and lateral extent of neoplasia inducing clinical intervention, as well as confirm cancer progression and assess margins.7

BE Patient management 2.png

"Cellvizio® adds 3-5 minutes, while more than doubling detection of Barrett's Esophagus vs. conventional biopsies."
Dr. A. McNair Jr., New Gulf Coast Surgery Center

1. Richardson C. et al.Real-time diagnosis of Barrett’s Esophagus: a prospective, multicenter study comparing confocal laser endomicroscopy with conventional histology for the identification of intestinal metaplasia in new users, Surgical Endoscopy, 2018.
2. Desai M. et al. Prevalence of HGD and adenocarcinoma on index endoscopy in BE, Gastrointest Endosc, 2018.
3. Burnette J. et al. Utility of probe-Based Confocal Laser Endomicroscopy in screening work-up for Barrett’s esophagus. Abstract at SAGES 2015.
4. Sharma P. et al. Real-time increased detection of Neoplastic tissue in Barrett’s Esophagus with pCLE; Final results of a multi-center prospective international randomized controlled trial, Gastrointest Endosc, 2011 (DONT BIOPSE).
5. Canto M. et al. In vivo endomicroscopy improves detection of Barrett’s Esophagus related neoplasia: a multicenter international randomized controlled trial, GIE, 2013.
6. Kiesslich R. et al. In vivo histology of Barrett’s Esophagus and Associated Neoplasia by CLE, Clinical Gastro and Hepatology, 2006.
7. Wang K. et al. Use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications. A consensus report based on clinical evidence. UEGW Journal, 2015.

Find out more by downloading the
Cellvizio Brochure